Financial insights of BVS

MyFinsight

Income Statement	2026-03-28	2025-12-31	2025-09-27	2025-06-28
Net sales	132,089	157,900	138,651	147,660
Cost of sales (including depreciation and amortization of 10,087 and 10,265, respectively)	41,320	49,118	44,422	45,570
Gross profit	90,769	108,782	94,229	102,090
Selling, general and administrative expense	78,325	82,757	78,657	79,110
Research and development expense	2,467	3,007	2,923	3,172
Restructuring costs	454	2,235*	NaN	NaN
Change in fair value of contingent consideration	NaN	0*	0	0
Depreciation and amortization	1,107	1,297	1,398	1,439
Impairment of assets	NaN	0*	0	0
Loss on disposals	0	0	1	-1
Operating income	8,416	19,486	11,252	18,368
Interest expense, net	-4,326	-5,306	-6,177	-7,494
Gain on extinguishment	NaN	0	-326	NaN
Other (income) expense	427	-37	-79	-561
Other expense	-3,899	-5,343	-6,582	-8,055
Income (loss) before income taxes	4,517	14,143	4,670	10,313
Income tax expense (benefit), net	571	-3,175	664	1,041
Net income (loss) from continuing operations	NaN	17,318*	NaN	NaN
Loss from discontinued operations, net of tax	NaN	0*	NaN	NaN
Net income (loss)	3,946	17,318	4,006	9,272
(income) loss attributable to noncontrolling interest - continuing operations	NaN	2,563*	NaN	NaN
Loss attributable to noncontrolling interest - discontinued operations	NaN	0*	NaN	NaN
(income) loss attributable to noncontrolling interest	833	NaN	851	1,813
Net income (loss) attributable to bioventus inc	3,113	14,755	3,155	7,459

Basic EPS	0.05	0.22	0.05	0.11
Diluted EPS	0.04	0.204	0.05	0.11
Basic Average Shares	67,296,336	67,056,726	66,924,682	66,500,433
Diluted Average Shares	70,008,291	72,276,341	68,837,797	68,536,759

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.